Compare ASTH & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTH | EVO |
|---|---|---|
| Founded | 1994 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4766 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | ASTH | EVO |
|---|---|---|
| Price | $25.41 | $3.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $41.33 | $7.00 |
| AVG Volume (30 Days) | ★ 531.7K | 259.6K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $2,896,452,000.00 | $887,396,457.00 |
| Revenue This Year | $58.46 | N/A |
| Revenue Next Year | $25.59 | $8.52 |
| P/E Ratio | $128.58 | ★ N/A |
| Revenue Growth | ★ 68.17 | N/A |
| 52 Week Low | $20.12 | $2.84 |
| 52 Week High | $39.97 | $5.10 |
| Indicator | ASTH | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 59.04 | 50.32 |
| Support Level | $21.98 | $3.03 |
| Resistance Level | $25.48 | $3.05 |
| Average True Range (ATR) | 0.99 | 0.09 |
| MACD | 0.57 | 0.03 |
| Stochastic Oscillator | 97.11 | 80.42 |
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.